Tag Archives: Daraprim
If President Trump truly intends to control drug costs, fixing drug pricing formulas and enhancing existing penalties could reduce costs for both public and private payers.
March 31, 2017
Meaningful intellectual property ownership for older medications expired decades ago, and they are now subject to massive price increases or severe shortages. This need not be the case, and there are remedies to address these problems.
February 23, 2016
The increasing number of specialty pharmaceuticals available is good news for the patients who sorely need these drugs to improve, or even reverse, their medical conditions. However, specialty pharmacy is also the fastest growing sector of pharmacy spending today.
November 19, 2015
The unfairness of a 5,000 percent price increase for the drug Daraprim has received attention. We believe the U.S. Department of Justice, Federal Trade Commission, state attorneys general, and private parties should review Turing’s behavior and consider bringing an antitrust case to challenge...
October 21, 2015